<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178034</url>
  </required_header>
  <id_info>
    <org_study_id>1643P</org_study_id>
    <nct_id>NCT01178034</nct_id>
  </id_info>
  <brief_title>Early Identification of Warfarin Maintenance Dosage</brief_title>
  <official_title>Early Identification of Warfarin Maintenance Dose in Patients With Atrial Fibrillation: a Randomized Trial Evaluating a New Genotype-based Versus Usual Care Initiation of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initiation of warfarin therapy is problematic. The investigators goal was to evaluate if a
      new demographic/pharmacogenetic algorithm is better than a usual algorithm based on INR value
      at day five after four days of 5 mg/day warfarin. To this end patients with atrial
      fibrillation starting warfarin are randomized in two arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this randomized study is to evaluate the accuracy of a new
      demographic/pharmacogenetic as compared to usual warfarin dosing algorithm in predicting
      warfarin maintenance dose. In patients with atrial fibrillation starting anticoagulation, the
      loading dose of warfarin in the tested group is calculated on the basis of VKORC1 genotype
      and patient's body weight.The second day warfarin maintenance dose is calculated on the basis
      of surface area and CYP2C9, CYP4F2 e VKORC1 genotype. In the usual care group the maintenance
      dose at day 5 is calculated on the basis of a published algorithm (Pengo V, Am J Cardiol
      2001). INR is checked on day 0, 5, 7, 9, 12, 15 and 19. Primary end-point of the trial is the
      number of INR outside the therapeutic range of 2.0 to 3.0. Secondary end-points are the
      number of changes in dose prescription, the difference between predicted and actual warfarin
      maintenance dose and thrombotic and bleeding events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Normalized Ratio (INR)</measure>
    <time_frame>Day 0, 5, 7, 9, 12, 15, 19.</time_frame>
    <description>Number of INR outside the therapeutic range (INR 2.0-3.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of changes in warfarin dosage</measure>
    <time_frame>Day 0-19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between predicted and actual warfarin maintenance dose</measure>
    <time_frame>Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic and Bleeding complications</measure>
    <time_frame>Day 0-30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>pharmacogenetic warfarin dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin maintenance dose on the basis of demographic/pharmacogenetic data</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Calculate warfarin dose using demographic/genetic algorithm</intervention_name>
    <description>Age, body weight and genetic to calculate warfarin dosage</description>
    <arm_group_label>pharmacogenetic warfarin dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Indication to warfarin with INR between 2.0 and 3.0

        Exclusion Criteria:

          -  Pregnancy

          -  Drug interactions

          -  Basal INR &gt; 1.2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vittorio Pengo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrombosis Centre</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>October 21, 2012</last_update_submitted>
  <last_update_submitted_qc>October 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Vittorio Pengo</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>Dose</keyword>
  <keyword>Pharmacogenetic</keyword>
  <keyword>INR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

